Harbor Capital Advisors Inc. Raises Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Harbor Capital Advisors Inc. boosted its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 67.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,302 shares of the biotechnology company's stock after acquiring an additional 35,102 shares during the period. Harbor Capital Advisors Inc. owned 0.15% of Ascendis Pharma A/S worth $13,035,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Signaturefd LLC grew its position in shares of Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock valued at $102,000 after purchasing an additional 80 shares in the last quarter. Bessemer Group Inc. raised its holdings in shares of Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company's stock worth $132,000 after acquiring an additional 332 shares during the period. Searle & CO. acquired a new position in shares of Ascendis Pharma A/S during the 2nd quarter valued at about $205,000. Rhumbline Advisers grew its holdings in shares of Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock valued at $209,000 after purchasing an additional 143 shares during the period. Finally, Pursue Wealth Partners LLC acquired a new stake in Ascendis Pharma A/S during the third quarter worth about $217,000.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ ASND traded up $2.46 during midday trading on Friday, hitting $125.28. 389,318 shares of the company's stock were exchanged, compared to its average volume of 386,164. Ascendis Pharma A/S has a twelve month low of $86.54 and a twelve month high of $161.00. The firm's fifty day simple moving average is $133.42 and its 200-day simple moving average is $133.62.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analysts' expectations of $94.74 million. As a group, equities research analysts forecast that Ascendis Pharma A/S will post -7.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Wells Fargo & Company upped their price objective on Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an "overweight" rating in a report on Tuesday, September 17th. Bank of America upped their price target on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a research note on Monday, September 23rd. StockNews.com raised Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Thursday, September 5th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, September 16th. Finally, Citigroup raised their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a "buy" rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $195.92.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.